Classification and personalized prognosis in myeloproliferative neoplasms

New England Journal of Medicine

Volumn 379, Issue 15, 2018, Pages 1416-1430

  Grinfeld, J ^a,b,c   Nangalia, J ^d   Baxter, E J ^b,c   Wedge, D C ^d,f   Angelopoulos, N ^d   Cantrill, R ^e   Godfrey, A L ^c   Papaemmanuil, E ^d,i   Gundem, G ^d,i   MacLean, C ^b,c   Cook, J ^b,c   O'Neil, L ^d   O'Meara, S ^d   Teague, J W ^d   Butler, A P ^d   Massie, C E ^a,b   Williams, N ^d   Nice, F L ^a,b   Andersen, C L ^j,k   Hasselbalch, H C ^j,k   Guglielmelli, P ^l   McMullin, M F ^g   Vannucchi, A M ^l   Harrison, C N ^h   Gerstung, M ^e   Green, A R ^a,b,c   Campbell, P J ^a,d   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^h GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j ZEALAND UNIVERSITY HOSPITAL   (Denmark)

^k UNIVERSITY OF COPENHAGEN   (Denmark)

^l CAREGGI UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CALRETICULIN, HUMAN; DNA; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MPL PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR;

BAYES THEOREM; CLASSIFICATION; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DNA SEQUENCE; GENETICS; HUMAN; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MUTATION; MYELOPROLIFERATIVE DISORDER; PERSONALIZED MEDICINE; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

BAYES THEOREM; CALRETICULIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; HUMANS; JANUS KINASE 2; MULTIVARIATE ANALYSIS; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; PRECISION MEDICINE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, THROMBOPOIETIN; SEQUENCE ANALYSIS, DNA;

EID: 85054773608     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1716614     Document Type: Article

References (40)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6: 372-5.
2. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-405.
3. Harrison CN, Butt N, Campbell P, et al. Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. Br J Haematol 2014; 167: 421-3.
4. McMullin MF, Reilly JT, Campbell P, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/ erythrocytosis. Br J Haematol 2007; 138: 821-2.
5. Reilly JT, McMullin MF, Beer PA, et al. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. Br J Haematol 2014; 167: 418-20.
6. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008; 111: 60-70.
7. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rethinking the diagnostic criteria of polycythemia vera. Leukemia 2014; 28: 1191-5.
8. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391-405.
9. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014; 123: 2220-8.
10. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861-9.
11. Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv 2016; 1: 21-30.
12. Tefferi A, Vannucchi AM. Genetic risk assessment in myeloproliferative neoplasms. Mayo Clin Proc 2017; 92: 1283-90.
13. Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med 2015; 372: 601-12.
14. Nangalia J, Nice FL, Wedge DC, et al. DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica 2015; 100(11): e438-42.
15. Taylor J, Xiao W, Abdel-Wahab O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood 2017; 130: 410-23.
16. Gerstung M, Papaemmanuil E, Martincorena I, et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet 2017; 49: 332-40.
17. Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 2017; 31: 2726-31.
18. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009; 41: 446-9.
19. Tapper W, Jones AV, Kralovics R, et al. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun 2015; 6: 6691.
20. van der Harst P, Zhang W, Mateo Leach I, et al. Seventy-five genetic loci influencing the human red blood cell. Nature 2012; 492: 369-75.
21. Ruark E, Snape K, Humburg P, et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 2013; 493: 406-10.
22. Zhang L, Chen LH, Wan H, et al. Exome sequencing identifies somatic gainof- function PPM1D mutations in brainstem gliomas. Nat Genet 2014; 46: 726-30.
23. Chen C, Liu Y, Rappaport AR, et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 2014; 25: 652-65.
24. Cabagnols X, Favale F, Pasquier F, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood 2016; 127: 333-42.
25. Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood 2016; 127: 325-32.
26. Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008; 372: 1484-92.
27. Wu Q-Y, Guo H-Y, Li F, Li Z-Y, Zeng L-Y, Xu K-L. Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations. Leuk Lymphoma 2013; 54: 2693-700.
28. Kearney L, Gonzalez De Castro D, Yeung J, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009; 113: 646-8.
29. Marty C, Saint-Martin C, Pecquet C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood 2014; 123: 1372-83.
30. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and bloodcancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-87.
31. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488-98.
32. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016; 374: 2209-21.
33. Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood 2014; 124: 1513-21.
34. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-27.
35. Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia 2017; 31: 705-11.
36. Hultcrantz M, Kristinsson SY, Andersson TM-L, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 2012; 30: 2995-3001.
37. Al Assaf C, Van Obbergh F, Billiet J, et al. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica 2015; 100: 893-7.
38. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-901.
39. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-8.
40. Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012; 120: 1197-201.